Literature DB >> 1486289

Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature.

J Atkinson1, M A Hrisinko, S C Weil.   

Abstract

Erythroleukemia (EL) is a rare form of myelogenous leukemia the classification and definition of which has evolved over the course of its 80-year descriptive history. In 1976 the French American British (FAB) Cooperative Group included EL within the classification system of acute myelogenous leukemias as AML-M6, and agreed on a quantitative standard to be used in the diagnosis of this disorder. The standards were revised in 1985 to the form in use today. We selected a series of 15 cases from our records which specifically fit the FAB criteria for AML-M6. Extensive direct comparison between our series and the old literature is not practical because of the changes which have occurred in classification and definition of the disease. Overall we found a rough correlation between the clinical and laboratory data shown in the old literature on EL and data from our cases. These cases underscore characteristic laboratory features which correspond to what is now defined as AML-M6: these patients present with pancytopenia, frequent peripheral blood nRBCs and no, or few, peripheral blood blasts. In addition, we note the presence of a hybrid myeloid-erythroid blast in the bone marrow in this disease and suggest that this may be characteristic of this type of AML. Old literature on EL has generally shown it to be a disease of the elderly, yet we found a subset of younger patients whose clinical outcome was significantly better than that of the older patients. Finally, EL has historically been viewed as a disease in which patients progress from a prodrome through erythroleukemia to other acute myeloid leukemia (AML) subtypes. Consistent with this idea, half of our 15 patients had been previously diagnosed with myelodysplastic syndrome or received chemotherapy. On the other hand only one of the 15 patients converted to another type of AML during his course.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486289     DOI: 10.1016/0268-960x(92)90016-j

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  6 in total

1.  Erythroleukaemia in the north of England: a population based study.

Authors:  A W Wells; N Bown; M M Reid; P J Hamilton; G H Jackson; P R Taylor
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

2.  More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Authors:  Guillermo Montalban-Bravo; Christopher B Benton; Sa A Wang; Farhad Ravandi; Tapan Kadia; Jorge Cortes; Naval Daver; Koichi Takahashi; Courtney DiNardo; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Sherry Pierce; Carlos Bueso-Ramos; Keyur Patel; Steven Kornblau; Hagop Kantarjian; Ken H Young; Guillermo Garcia-Manero; Michael Andreeff
Journal:  Blood       Date:  2017-02-28       Impact factor: 22.113

3.  Pure Erythroleukemia (Variant Acute Myeloid Leukemia-vAML-M6) with Deletion of Chromosome 20, Mainly Presenting as Late Erythroblasts, a Unique Case Report with Review of Literature.

Authors:  Javid Rasool; Sajad Geelani; Mohd Suhail Lone; Mohd Shaban
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-05       Impact factor: 0.900

4.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

5.  Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Authors:  Antonio M Almeida; Thomas Prebet; Raphael Itzykson; Fernando Ramos; Haifa Al-Ali; Jamile Shammo; Ricardo Pinto; Luca Maurillo; Jaime Wetzel; Pellegrino Musto; Arjan A Van De Loosdrecht; Maria Joao Costa; Susana Esteves; Sonja Burgstaller; Reinhard Stauder; Eva M Autzinger; Alois Lang; Peter Krippl; Dietmar Geissler; Jose Francisco Falantes; Carmen Pedro; Joan Bargay; Guillermo Deben; Ana Garrido; Santiago Bonanad; Maria Diez-Campelo; Sylvain Thepot; Lionel Ades; Wolfgang R Sperr; Peter Valent; Pierre Fenaux; Mikkael A Sekeres; Richard Greil; Lisa Pleyer
Journal:  Int J Mol Sci       Date:  2017-04-14       Impact factor: 5.923

6.  Association between NAT2 polymorphisms and acute leukemia risk: A meta-analysis.

Authors:  Xiaoxiao Zhu; Yanbing Liu; Guangwu Chen; Qiang Guo; Zhen Zhang; Lin Zhao; Ran Wei; Xunqiang Yin; Yunhong Zhang; Bin Wang; Xia Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.